Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Market Analysis and Insights: Global Neurological Disorder Drugs Market
Prior to COVID-19, the market for Neurological Disorder Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Neurological Disorder Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Neurological Disorder Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neurological Disorder Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Neurological Disorder Drugs industry.
Global Neurological Disorder Drugs Scope and Segment
Neurological Disorder Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
...
Neurological Disorder Drugs Breakdown Data by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Neurological Disorder Drugs Breakdown Data by Application
Hospital
Clinic
Regional and Country-level Analysis
The Neurological Disorder Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurological Disorder Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Market Analysis and Insights: Global Neurological Disorder Drugs Market
Prior to COVID-19, the market for Neurological Disorder Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Neurological Disorder Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Neurological Disorder Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neurological Disorder Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Neurological Disorder Drugs industry.
Global Neurological Disorder Drugs Scope and Segment
Neurological Disorder Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
...
Neurological Disorder Drugs Breakdown Data by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Neurological Disorder Drugs Breakdown Data by Application
Hospital
Clinic
Regional and Country-level Analysis
The Neurological Disorder Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurological Disorder Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
1 Study Coverage
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market Segments
1.3 Key Neurological Disorder Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neurological Disorder Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurological Disorder Drugs Revenue 2015-2026
2.1.2 Global Neurological Disorder Drugs Sales 2015-2026
2.2 Global Neurological Disorder Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neurological Disorder Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neurological Disorder Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neurological Disorder Drugs Competitor Landscape by Players
3.1 Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Neurological Disorder Drugs Sales by Manufacturers (2015-2020)
3.1.2 Neurological Disorder Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Neurological Disorder Drugs Revenue by Manufacturers
3.2.1 Neurological Disorder Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2019
3.2.5 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neurological Disorder Drugs Price by Manufacturers
3.4 Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurological Disorder Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neurological Disorder Drugs Market Size by Type (2015-2020)
4.1.1 Global Neurological Disorder Drugs Sales by Type (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue by Type (2015-2020)
4.1.3 Neurological Disorder Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurological Disorder Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neurological Disorder Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurological Disorder Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neurological Disorder Drugs Market Size by Application (2015-2020)
5.1.1 Global Neurological Disorder Drugs Sales by Application (2015-2020)
5.1.2 Global Neurological Disorder Drugs Revenue by Application (2015-2020)
5.1.3 Neurological Disorder Drugs Price by Application (2015-2020)
5.2 Neurological Disorder Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurological Disorder Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neurological Disorder Drugs by Country
6.1.1 North America Neurological Disorder Drugs Sales by Country
6.1.2 North America Neurological Disorder Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neurological Disorder Drugs Market Facts & Figures by Type
6.3 North America Neurological Disorder Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Neurological Disorder Drugs by Country
7.1.1 Europe Neurological Disorder Drugs Sales by Country
7.1.2 Europe Neurological Disorder Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neurological Disorder Drugs Market Facts & Figures by Type
7.3 Europe Neurological Disorder Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neurological Disorder Drugs by Region
8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Region
8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Type
8.3 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neurological Disorder Drugs by Country
9.1.1 Latin America Neurological Disorder Drugs Sales by Country
9.1.2 Latin America Neurological Disorder Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neurological Disorder Drugs Market Facts & Figures by Type
9.3 Central & South America Neurological Disorder Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neurological Disorder Drugs by Country
10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Country
10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Description and Business Overview
11.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
11.2.5 GlaxoSmithKline plc Related Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Description and Business Overview
11.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
11.3.5 Merck & Co. Related Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Description and Business Overview
11.4.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer AG Neurological Disorder Drugs Products Offered
11.4.5 Bayer AG Related Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Description and Business Overview
11.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
11.5.5 AstraZeneca Related Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Corporation Information
11.6.2 Boehringer Ingelheim GmbH Description and Business Overview
11.6.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
11.6.5 Boehringer Ingelheim GmbH Related Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Corporation Information
11.7.2 Teva Pharmaceutical Description and Business Overview
11.7.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
11.7.5 Teva Pharmaceutical Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neurological Disorder Drugs Market Estimates and Projections by Region
12.1.1 Global Neurological Disorder Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Neurological Disorder Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.2.2 North America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neurological Disorder Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Neurological Disorder Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurological Disorder Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market Segments
1.3 Key Neurological Disorder Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neurological Disorder Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurological Disorder Drugs Revenue 2015-2026
2.1.2 Global Neurological Disorder Drugs Sales 2015-2026
2.2 Global Neurological Disorder Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neurological Disorder Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neurological Disorder Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neurological Disorder Drugs Competitor Landscape by Players
3.1 Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Neurological Disorder Drugs Sales by Manufacturers (2015-2020)
3.1.2 Neurological Disorder Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Neurological Disorder Drugs Revenue by Manufacturers
3.2.1 Neurological Disorder Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2019
3.2.5 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neurological Disorder Drugs Price by Manufacturers
3.4 Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurological Disorder Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neurological Disorder Drugs Market Size by Type (2015-2020)
4.1.1 Global Neurological Disorder Drugs Sales by Type (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue by Type (2015-2020)
4.1.3 Neurological Disorder Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurological Disorder Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neurological Disorder Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurological Disorder Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neurological Disorder Drugs Market Size by Application (2015-2020)
5.1.1 Global Neurological Disorder Drugs Sales by Application (2015-2020)
5.1.2 Global Neurological Disorder Drugs Revenue by Application (2015-2020)
5.1.3 Neurological Disorder Drugs Price by Application (2015-2020)
5.2 Neurological Disorder Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurological Disorder Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neurological Disorder Drugs by Country
6.1.1 North America Neurological Disorder Drugs Sales by Country
6.1.2 North America Neurological Disorder Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neurological Disorder Drugs Market Facts & Figures by Type
6.3 North America Neurological Disorder Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Neurological Disorder Drugs by Country
7.1.1 Europe Neurological Disorder Drugs Sales by Country
7.1.2 Europe Neurological Disorder Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neurological Disorder Drugs Market Facts & Figures by Type
7.3 Europe Neurological Disorder Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neurological Disorder Drugs by Region
8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Region
8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Type
8.3 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neurological Disorder Drugs by Country
9.1.1 Latin America Neurological Disorder Drugs Sales by Country
9.1.2 Latin America Neurological Disorder Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neurological Disorder Drugs Market Facts & Figures by Type
9.3 Central & South America Neurological Disorder Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neurological Disorder Drugs by Country
10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Country
10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Description and Business Overview
11.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
11.2.5 GlaxoSmithKline plc Related Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Description and Business Overview
11.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
11.3.5 Merck & Co. Related Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Description and Business Overview
11.4.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer AG Neurological Disorder Drugs Products Offered
11.4.5 Bayer AG Related Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Description and Business Overview
11.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
11.5.5 AstraZeneca Related Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Corporation Information
11.6.2 Boehringer Ingelheim GmbH Description and Business Overview
11.6.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
11.6.5 Boehringer Ingelheim GmbH Related Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Corporation Information
11.7.2 Teva Pharmaceutical Description and Business Overview
11.7.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
11.7.5 Teva Pharmaceutical Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neurological Disorder Drugs Market Estimates and Projections by Region
12.1.1 Global Neurological Disorder Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Neurological Disorder Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.2.2 North America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neurological Disorder Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Neurological Disorder Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurological Disorder Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
